MétaCan
Menu
Back to cohort
Record W2006246160 · doi:10.1016/j.juro.2010.02.1473

797 DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY

2010· article· en· W2006246160 on OpenAlexaboutno aff
J. Curtis Nickel, Teuvo L.J. Tammela, Cláudio Telöken, Timothy H. Wilson, Ivy L. Fowler, Roger S. Rittmaster

Bibliographic record

VenueThe Journal of Urology · 2010
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsnot available
Fundersnot available
KeywordsDutasterideMedicineProstatitisPlaceboProstate cancerUrologyProstateGynecologyTestosterone (patch)Prostate biopsyInternal medicineCancerAlternative medicinePathology

Abstract

fetched live from OpenAlex

You have accessJournal of UrologyInfections/Inflammation of the Genitourinary Tract: Prostate & Genitalia1 Apr 2010797 DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY J. Curtis Nickel, Teuvo L.J. Tammela, Claudio Teloken, Timothy H. Wilson, Ivy L. Fowler, and Roger S. Rittmaster J. Curtis NickelJ. Curtis Nickel Kingston, Canada More articles by this author , Teuvo L.J. TammelaTeuvo L.J. Tammela Tampere, Finland More articles by this author , Claudio TelokenClaudio Teloken Porto Alegre, Brazil More articles by this author , Timothy H. WilsonTimothy H. Wilson Research Triangle Park, NC More articles by this author , Ivy L. FowlerIvy L. Fowler Research Triangle Park, NC More articles by this author , and Roger S. RittmasterRoger S. Rittmaster Research Triangle Park, NC More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1473AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES REDUCE is a completed 4-year study of prostate cancer risk reduction with dutasteride. This analysis examines the effects of dutasteride vs. placebo on prostatitis-like symptoms as measured by the Chronic Prostatitis Symptom Index (CPSI). METHODS CPSI was administered at baseline and every 6 months in men (aged ≥50 and ≤75 years, who had a serum PSA ≥2.5 and ≤10 ng/ml and negative baseline biopsy) randomized to dutasteride or placebo. Changes in total and sub scores of the CPSI from baseline were compared in patients identified with prostatitis-like pain (CPSI pain sub score ≥5) and prostatitis-like syndrome (perineal and/or ejaculatory pain + CPSI pain sub score ≥4), using a general linear model with effects for baseline score. Comparison of responders, defined as those who had at least a 4-point (at least minimal response) or 6-point (at least moderate response) decrease in total CPSI were compared using the Fisher′s Exact Test. RESULTS CPSI score was available in 2682 and 2696 men in the placebo and dutasteride groups, respectively. There were 337 (mean CPSI 15.36) and 328 (mean CPSI 14.96) men with prostatitis-like pain and 182 (mean CPSI 14.92) and 184 (mean CPSI 14.93) men with prostatitis-like syndrome identified at baseline in the placebo and dutasteride groups, respectively. There was a significant decrease in total and most sub-scores of the CPSI at 48 months in the dutasteride group compared with the placebo group (Table). In the prostatitis-like pain subgroup and prostatitis-like syndrome subgroup, there were significantly more 4-point responders (63.3% and 58.6% respectively) and 6-point responders (49.2% and 46.6% respectively) in the dutasteride groups compared with placebo groups (49.8 % and 45.4% respectively for 4-point responders; 37.5% and 32.8% respectively for 6-point responders). Table. Mean changes in Chronic Prostatitis Symptom Index (CPSI) sub-scores from baseline Mean change from baseline at Month 48 Patient groups Total CPSI CPSI Pain CPSI Urinary CPSI QoL Prostatitis-like pain Placebo -2.84 -2.93 0.37 -0.21 Dutasteride -5.35 -3.92 -0.78 -0.53 p value <0.0001 0.0008 <0.0001 0.0005 Prostatitis-like syndrome Placebo -2.47 -2.64 0.31 -0.24 Dutasteride -4.60 -3.33 -0.65 -0.46 p value 0.0031 0.0890 0.0033 0.0719 CONCLUSIONS Treatment with dutasteride over 4 years improved prostatitis-related symptoms in older men identified with prostatitis-like pain and prostatitis-like syndrome. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e311-e312 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information J. Curtis Nickel Kingston, Canada More articles by this author Teuvo L.J. Tammela Tampere, Finland More articles by this author Claudio Teloken Porto Alegre, Brazil More articles by this author Timothy H. Wilson Research Triangle Park, NC More articles by this author Ivy L. Fowler Research Triangle Park, NC More articles by this author Roger S. Rittmaster Research Triangle Park, NC More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.016
Threshold uncertainty score0.054

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0160.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.339
Teacher spread0.321 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2010
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of UrologySame topicProstate Cancer Treatment and ResearchFrench-language works237,207